Melbourne, Australia

Yevgen Bilotsky

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Seqvera Ltd. Oy. Active years: 2019.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2019

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Yevgen Bilotsky: Innovator in Biomaterials Testing

Introduction

Yevgen Bilotsky is a notable inventor based in Melbourne, Australia. He has made significant contributions to the field of biomaterials through his innovative research and development. His work focuses on advancing methods for evaluating the properties of biomaterials, which are crucial for various applications in medicine and engineering.

Latest Patents

Yevgen Bilotsky holds a patent for an "In vitro method for measurement and model-free evaluation of time-invariant biomaterials functions." This invention discloses a method for in vitro testing of specimens, such as biomaterials, to obtain history-dependent, time-invariant functional materials properties using time-convolution and idempotent analysis. The purpose of this method is to measure these properties using data processing without limitations of materials models, the properties linearity, or material homogeneity. He has 1 patent to his name.

Career Highlights

Yevgen Bilotsky is currently associated with Seqvera Ltd. Oy, where he continues to push the boundaries of biomaterials research. His work has garnered attention for its innovative approach and practical applications in the field.

Collaborations

Yevgen has collaborated with Michael Gasik, contributing to the advancement of their shared research interests in biomaterials.

Conclusion

Yevgen Bilotsky's contributions to the field of biomaterials through his innovative patent and ongoing research at Seqvera Ltd. Oy highlight his role as a significant inventor in this important area of study.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…